GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Net Margin %
中文

Aravive (STU:VE11) Net Margin % : 770.29% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

Aravive Net Margin % Definition

Net margin is calculated as Net Income divided by its Revenue. Aravive's Net Income for the three months ended in Sep. 2023 was €19.89 Mil. Aravive's Revenue for the three months ended in Sep. 2023 was €2.58 Mil. Therefore, Aravive's net margin for the quarter that ended in Sep. 2023 was 770.29%.

The historical rank and industry rank for Aravive's Net Margin % or its related term are showing as below:

STU:VE11' s Net Margin % Range Over the Past 10 Years
Min: -5567.69   Med: -531.67   Max: -212.45
Current: -569.65


STU:VE11's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -163.08 vs STU:VE11: -569.65

Aravive Net Margin % Historical Data

The historical data trend for Aravive's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Net Margin % Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,568.22 -383.26 -537.26 -526.10 -835.34

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -316.02 -1,976.56 -3,349.53 1,413.35 770.29

Competitive Comparison of Aravive's Net Margin %

For the Biotechnology subindustry, Aravive's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Aravive's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aravive's Net Margin % falls into.



Aravive Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aravive's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-72.048/8.625
=-835.34 %

Aravive's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=19.889/2.582
=770.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aravive  (STU:VE11) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Aravive Net Margin % Related Terms

Thank you for viewing the detailed overview of Aravive's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (STU:VE11) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines